Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 14/20 | 0.51 |
| ▸ | HTR3A | P46098 | 14/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.47 |
| ▸ | HTR6 | P50406 | 4/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.46 |
| ▸ | HTR2C | P28335 | 3/20 | 0.46 |
| ▸ | HRH1 | P35367 | 3/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.46 |
| ▸ | HTR1B | P28222 | 3/20 | 0.46 |
| ▸ | HTR7 | P34969 | 3/20 | 0.46 |
| ▸ | HTR5A | P47898 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | HRH2 | P25021 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19619032 | 0.79 | HTR1A (0.71) | HTR1AHTR3AADRB1HTR6ADRB2 | |
| SCHEMBL255197 | 0.78 | HTR3A (0.67) | HTR1AHTR3AADRB1HTR6ADRB2 | |
| SCHEMBL27848226 | 0.77 | ALDH1A1 (0.57) | — | |
| SCHEMBL22542113 | 0.77 | HTR3A (0.48) | HTR1AHTR3AADRB1HTR6ADRB2 | |
| SCHEMBL17281590 | 0.76 | ADRB1 (0.56) | HTR1AHTR3AADRB1HTR6HTR1B | |
| SCHEMBL233944 | 0.76 | HTR3A (0.61) | HTR1AHTR3AADRB1HTR6ADRB2 | |
| Hydrochloric Acid SCHEMBL2534803 | 0.76 | HTR3A (0.68) | HTR1AHTR3AADRB1HTR6ADRB2 | |
| SCHEMBL13398441 | 0.75 | HTR3A (0.55) | HTR1AHTR3AADRB1HTR6ADRB2 | |
| SCHEMBL8699310 | 0.75 | HTR3A (0.55) | HTR1AHTR3AADRB1HTR6ADRB2 | |
| SCHEMBL3920957 | 0.75 | HTR3A (0.55) | HTR1AHTR3AADRB1HTR6ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102239152-B | Novel amide derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORP. (JP) | 2014-10-29 | — | — | CN | disclosed |
| EP-2364975-B1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-06-12 | — | — | EP | disclosed |
| US-8354401-B2 | Oxazolidinone amide aromatic compounds for supressing MMP-9 production | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-01-15 | — | — | US | disclosed |
| CN-102239152-A | Novel amide derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORP | 2011-11-09 | — | — | CN | disclosed |
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2364975-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP2 | HTR1A 4013/4885HTR3A 3071/4885ADRB1 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.